home / stock / bfra / bfra news

BFRA News and Press, Biofrontera AG From 11/12/20

Stock Information
Company Name: Biofrontera AG
Stock Symbol: BFRA
Market: NASDAQ
Menu
BFRA BFRA Quote BFRA Short BFRA News BFRA Articles BFRA Message Board
Get BFRA Alerts

News, Short Squeeze, Breakout and More Instantly...
BFRA - Biofrontera AG resolves mandatory conversion of subordinated mandatory convertible bonds

Leverkusen, Germany, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has issued a 1.00% qualified subordinated mandatory convertible bond 2020/2021 (ISIN: DE000A3E45...
BFRA - Biofrontera reports Q3 results

Biofrontera (BFRA): Q3 loss from operations of €4.0M.Revenue of €4.7M (-8.7% Y/Y).Cash and cash equivalents of €16.6M.Press Release For further details see: Biofrontera reports Q3 results

BFRA - Biofrontera reports third quarter and first nine months 2020 results

Leverkusen, Germany, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today published its results for the third quarter ended September 30, 2020. In addition, the Com...

BFRA - Biofrontera announces conference call to be held on November 12, 2020 to discuss Q3 2020 financial results

Leverkusen, Germany, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its unaudited financial results for the third quarter ended September 30, 2020...
BFRA - Biofrontera AG: Receives reasons from the Federal Court of Justice for overturning ruling of the Cologne Higher Regional Court

Leverkusen, Germany, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, had announced on September 22, 2020, that in a ruling from September 22, 2020, the German Federa...

BFRA - Biofrontera provides preliminary revenue figures

The Biofrontera-Group ([[BFRA]]) Q3 preliminary revenue €4.7M-4.9M, about 9% less than in Q3 2019.Company generated total preliminary unaudited revenue of ~€20.8M-21.0M in the period from January 1st to September 30th, 2020, representing 9% growth from last year.In ...

BFRA - Biofrontera reports preliminary unaudited sales revenue for the third quarter of 2020

Leverkusen, Germany, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports preliminary unaudited revenue for the third quarter of fiscal year 2020. The...
BFRA - Biofrontera concludes clinical phase of PK study with Ameluz gel in actinic keratoses

Biofrontera ([[BFRA]] -1.9%) has completed clinical phase of pharmacokinetics ((PK)) study to test the safety of photodynamic therapy ((PDT)) using three tubes of Ameluz, at the same time.Ameluz gel is a prescription drug for photodynamic therapy for mild- to-moderate actinic keratoses.The ma...

BFRA - Biofrontera AG reports completion of the clinical phase of the pharmacokinetics study

Leverkusen, Germany, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, reports the completion of the clinical phase (last subject last visit) of the pharmacokinetics s...

BFRA - Biofrontera AG: German Federal Supreme Court overturns ruling of the Cologne Higher Regional Court

Leverkusen, Germany, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that in ruling on September 22, 2020, the German Federal Supreme Court overturned a d...
Previous 10 Next 10